Top

Osteoporosis International

Published in:

01-03-2018 | Original Article

Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors

Authors: S. S. L. Goh, P. S. M. Lai, A. T. B. Tan, S. Ponnampalavanar

Published in: Osteoporosis International | Issue 3/2018

Abstract

Summary

A meta-analysis was conducted to evaluate the prevalence of osteopenia/osteoporosis in human immunodeficiency virus (HIV)-infected individuals. The prevalence of osteopenia/osteoporosis in HIV-infected and antiretroviral therapy (ART)-treated individuals was significantly higher than respective controls. Evidence regarding bone loss within first year of HIV infection or ART initiation was preliminary.

Purpose

The aim of the study is to systematically review published literature on the prevalence of osteopenia/osteoporosis and its associated risk factors in HIV-infected individuals.

Methods

A literature search was conducted from 1989 to 2015 in six databases. Full text, English articles on HIV-infected individuals ≥ 18 years, which used dual X-ray absorptiometry to measure BMD, were included. Studies were excluded if the prevalence of osteopenia/osteoporosis was without a comparison group, and the BMD/T-score were not reported.

Results

Twenty-one cross sectional and eight longitudinal studies were included. The prevalence of osteopenia/osteoporosis was significantly higher in both HIV-infected [odds ratio (OR) = 2.4 (95%Cl: 2.0, 2.8) at lumbar spine, 2.6 (95%Cl: 2.2, 3.0) at hip] and ART-treated individuals [OR = 2.8 (95%Cl: 2.0, 3.8) at lumbar spine, 3.4 (95%Cl: 2.5, 4.7) at hip] when compared to controls. PI-treated individuals had an OR of 1.3 (95%Cl: 1.0, 1.7) of developing osteopenia/osteoporosis compared to controls. A higher proportion of tenofovir-treated individuals (52.6%) had lower BMD compared to controls (42.7%), but did not reach statistical significance (p = 0.248). No significant difference was found in the percent change of BMD at the lumbar spine, femoral neck, or total hip from baseline to follow-up between HIV-infected, PI-treated, tenofovir-treated, and controls. Older age, history of bone fracture, low BMI, low body weight, being Hispanic or Caucasian, low testosterone level, smoking, low CD4 cell count, lipodystrophy, low fat mass, and low lean body mass were associated with low BMD.

Conclusions

The prevalence of osteopenia/osteoporosis in HIV-infected and antiretroviral therapy (ART)-treated individuals was two times more compared to controls. However, evidence concerning bone loss within the first year of HIV infection and ART initiation was preliminary.

Available only for authorised users

Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS (2007) Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 21(5):617–623. https://doi.org/10.1097/QAD.0b013e3280148c05 CrossRefPubMedPubMedCentral

Onen NF et al (2010) Aging and HIV infection: a comparison between older HIV-infected persons and the general population. HIV Clin Trials 11(2):100–109. https://doi.org/10.1310/hct1102-100 CrossRefPubMed

McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, Aldrovandi GM, Cardoso SW, Santana JL, Brown TT (2010) Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 51(8):937–946. https://doi.org/10.1086/656412 CrossRefPubMedPubMedCentral

Brown TT, Qaqish RB (2006) Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 20(17):2165–2174. https://doi.org/10.1097/QAD.0b013e32801022eb CrossRefPubMed

Foundation, N.O. Bone density exam or testing. 2017; Available from: https://www.nof.org/patients/diagnosis-information/bone-density-examtesting/

Dong HV, Cortés YI, Shiau S, Yin MT (2014) Osteoporosis and fractures in HIV/hepatitis C virus coinfection: a systematic review and meta-analysis. AIDS 28(14):2119–2131. https://doi.org/10.1097/QAD.0000000000000363 CrossRefPubMedPubMedCentral

National Institutes of Health, Quality assessment tool for observational cohort and cross-sectional studies National Institutes of Health, 2014

Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM, Atkins D (2001) Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med 20(3 Suppl):21–35. https://doi.org/10.1016/S0749-3797(01)00261-6 CrossRefPubMed

Amiel C, Ostertag A, Slama L, Baudoin C, N'Guyen T, Lajeunie E, Neit-Ngeilh L, Rozenbaum W, de Vernejoul MC (2004) BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 19(3):402–409. https://doi.org/10.1359/JBMR.0301246 CrossRefPubMed

10.

Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE (2006) HIV infection and bone mineral density in middle-aged women. Clin Infect Dis 42(7):1014–1020. https://doi.org/10.1086/501015 CrossRefPubMed

11.

Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Woodhouse AF, Gamble GD, Reid IR (2006) Bone mineral density is not reduced in HIV-infected Caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol 65(2):191–197. https://doi.org/10.1111/j.1365-2265.2006.02572.x CrossRef

12.

Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, Timpone J (2004) Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clinical Endocrinology Metabolism 89(3):1200–1206. https://doi.org/10.1210/jc.2003-031506 CrossRef

13.

Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J (2003) Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 17(13):1917–1923. https://doi.org/10.1097/00002030-200309050-00010 CrossRefPubMed

14.

Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S (2004) Reduced bone density in HIV-infected women. AIDS 18(3):475–483. https://doi.org/10.1097/00002030-200402200-00014 CrossRefPubMed

15.

Grijsen ML, Vrouenraets SME, Wit FWNM, Stolte IG, Prins M, Lips P, Reiss P, Prins JM (2013) Low bone mineral density, regardless of HIV status, in men who have sex with men. J Infect Dis 207(3):386–391. https://doi.org/10.1093/infdis/jis687 CrossRefPubMed

16.

Jones S, Restrepo D, Kasowitz A, Korenstein D, Wallenstein S, Schneider A, Keller MJ (2008) Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int 19(7):913–918. https://doi.org/10.1007/s00198-007-0524-8 CrossRefPubMed

17.

Loiseau-Pérès S, Delaunay C, Poupon S, Lespessailles E, Ballouche N, Arsac P, Benhamou CL (2002) Osteopenia in patients infected by the human immunodeficiency virus. A case control study. Joint Bone Spine 69(5):482–485. https://doi.org/10.1016/S1297-319X(02)00433-5 CrossRefPubMed

18.

Madeddu G, Spanu A, Solinas P, Calia GM, Lovigu C, Chessa F, Mannazzu M, Falchi A, Mura MS, Madeddu G (2004) Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Quarterly J Nuclear Medicine Molecular Imaging 48(1):39–48

19.

Negredo E, Domingo P, Ferrer E, Estrada V, Curran A, Navarro A, Isernia V, Rosales J, Pérez-Álvarez N, Puig J, Bonjoch A, Echeverría P, Podzamczer D, Clotet B (2014) Peak bone mass in young HIV-infected patients compared with healthy controls. Jaids-J Acquired Immune Deficiency Syndromes 65(2):207–212. https://doi.org/10.1097/01.qai.0000435598.20104.d6 CrossRef

20.

Tebas P, Powderly WG, Claxton S, Marin D, Tantisiriwat W, Teitelbaum SL, Yarasheski KE (2000) Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 14(4):F63–F67. https://doi.org/10.1097/00002030-200003100-00005 CrossRefPubMedPubMedCentral

21.

Teichmann J, Stephan E, Lange U, Discher T, Friese G, Lohmeyer J, Stracke H, Bretzel RG (2003) Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect 46(4):221–227. https://doi.org/10.1053/jinf.2002.1109 CrossRefPubMed

22.

Teichmann J, Lange U, Discher T, Lohmeyer J, Stracke H, Bretzel RG (2009) Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART). Eur J Med Res 14(2):59–64. https://doi.org/10.1186/2047-783X-14-2-59 CrossRefPubMedPubMedCentral

23.

Aydın OA, Karaosmanoglu HK, Karahasanoglu R, Tahmaz M, Nazlıcan O (2013) Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients. Braz J Infect Dis 17(6):707–711. https://doi.org/10.1016/j.bjid.2013.05.009 CrossRefPubMed

24.

Carr A, Miller J, Eisman JA, Cooper DA (2001) Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 15(6):703–709. https://doi.org/10.1097/00002030-200104130-00005 CrossRefPubMed

25.

de Menezes Barbosa EG et al (2013) Impact of antiretroviral therapy on bone metabolism markers in HIV-seropositive patients. Bone 57(1):62–67. https://doi.org/10.1016/j.bone.2013.07.019 CrossRef

26.

Garcia Aparicio AM et al (2006) Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol 25(4):537–539. https://doi.org/10.1007/s10067-005-0028-x CrossRefPubMed

27.

Libois A, Clumeck N, Kabeya K, Gerard M, de Wit S, Poll B, Tondeur M, Rozenberg S (2010) Risk factors of osteopenia in HIV-infected women: no role of antiretroviral therapy. Maturitas 65(1):51–54. https://doi.org/10.1016/j.maturitas.2009.10.009 CrossRefPubMed

28.

Tomazic J et al (2007) Prevalence and risk factors for osteopenia/osteoporosis in an HIV-infected male population. Wien Klin Wochenschr 119(21–22):639–646. https://doi.org/10.1007/s00508-007-0844-x CrossRefPubMed

29.

Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, Samaras K, Hesse K, Hirschel B, Cooper DA, Carr A (2009) Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis 200(11):1746–1754. https://doi.org/10.1086/644785 CrossRefPubMed

30.

Bolland MJ, Grey A, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, Gamble GD, Reid IR (2012) Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART). Clin Endocrinol 76(5):643–648. https://doi.org/10.1111/j.1365-2265.2011.04274.x CrossRef

31.

Dolan SE, Kanter JR, Grinspoon S (2006) Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 91(8):2938–2945. https://doi.org/10.1210/jc.2006-0127 CrossRefPubMedPubMedCentral

32.

Bonnet E et al (2013) Early loss of bone mineral density is correlated with a gain of fat mass in patients starting a protease inhibitor containing regimen: the prospective Lipotrip study. BMC Infect Dis 13(293):1–10

33.

Hansen AB, Obel N, Nielsen H, Pedersen C, Gerstoft J (2011) Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial. HIV Medicine 12(3):157–165. https://doi.org/10.1111/j.1468-1293.2010.00864.x CrossRefPubMed

34.

Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, Hoffmann M, Tebas P (2003) Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 36(4):482–490. https://doi.org/10.1086/367569 CrossRefPubMed

35.

Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK, 903 Study Group et al (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. J Am Med Assoc 292(2):191–201. https://doi.org/10.1001/jama.292.2.191 CrossRef

36.

Haskelberg H et al (2012) Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. PLoS One 7(6):1–9CrossRef

37.

Fakruddin JM, Laurence J (2003) HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 278(48):48251–48258. https://doi.org/10.1074/jbc.M304676200 CrossRefPubMed

38.

Knobel H, Guelar A, Vallecillo G, Nogués X, Díez A (2001) Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 15(6):807–808. https://doi.org/10.1097/00002030-200104130-00022 CrossRefPubMed

39.

Yin M, Dobkin J, Brudney K, Becker C, Zadel JL, Manandhar M, Addesso V, Shane E (2005) Bone mass and mineral metabolism in HIV plus postmenopausal women. Osteoporos Int 16(11):1345–1352. https://doi.org/10.1007/s00198-005-1845-0 CrossRefPubMedPubMedCentral

40.

Nakagawa F, May M, Phillips A (2013) Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis 26(1):17–25. https://doi.org/10.1097/QCO.0b013e32835ba6b1 CrossRefPubMed

41.

Taylor A, Rogers M HIV treatments and the skeleton: do NRTIs directly effect bone cells? Bone 46:S56

42.

Pan G, Wu X, McKenna MA, Feng X, Nagy TR, McDonald JM (2004) AZT enhances osteoclastogenesis and bone loss. AIDS Res Hum Retrovir 20(6):608–620. https://doi.org/10.1089/0889222041217482 CrossRefPubMed

43.

Ofotokun I, Weitzmann MN (2011) HIV and bone metabolism. Discov Med 11(60):385–393PubMedPubMedCentral

44.

Wang MW et al (2004) The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest 114(2):206–213. https://doi.org/10.1172/JCI15797 CrossRefPubMedPubMedCentral

45.

Walker Harris V, Brown TT (2012) Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis 205(Suppl 3):S391–S398. https://doi.org/10.1093/infdis/jis199 CrossRefPubMedPubMedCentral

46.

Davey J, Turner RM, Clarke MJ, Higgins JPT (2011) Characteristics of meta-analyses and their component studies in the Cochrane database of systematic reviews: a cross-sectional, descriptive analysis. BMC Med Res Methodol 11(1):160. https://doi.org/10.1186/1471-2288-11-160 CrossRefPubMedPubMedCentral

47.

Clarke BL, Khosla S (2010) Physiology of bone loss. Radiol Clin N Am 48(3):483–495. https://doi.org/10.1016/j.rcl.2010.02.014 CrossRefPubMedPubMedCentral

48.

Brown TT, Hoy J, Borderi M, Guaraldi G, Renjifo B, Vescini F, Yin MT, Powderly WG (2015) Recommendations for evaluation and management of bone disease in HIV. Clin Infect Dis 60(8):1242–1251. https://doi.org/10.1093/cid/civ010 CrossRefPubMedPubMedCentral

49.

Chiţu-Tișu C-E, Barbu EC, Lazăr M, Ion DA, Bădărău IA (2016) Low bone mineral density and associated risk factors in HIV-infected patients. Germs 6(2):50–59. 10.11599/germs.2016.1089 CrossRefPubMedPubMedCentral

50.

Erlandson KM, Allshouse AA, Jankowski CM, MaWhinney S, Kohrt WM, Campbell TB (2013) Functional impairment is associated with low bone and muscle mass among persons aging with HIV-infection. J Acquired Immune Deficiency Syndromes (1999) 63(2):209–215. https://doi.org/10.1097/QAI.0b013e318289bb7e CrossRef

51.

Shapses SA, Sukumar D (2012) Bone metabolism in obesity and weight loss. Annu Rev Nutr 32(1):287–309. https://doi.org/10.1146/annurev.nutr.012809.104655 CrossRefPubMedPubMedCentral

52.

Fiorenza CG, Chou SH, Mantzoros CS (2011) Lipodystrophy: pathophysiology and advances in treatment. Nat Rev Endocrinol 7(3):137–150. https://doi.org/10.1038/nrendo.2010.199 CrossRefPubMed

53.

Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J, Riddler S, Tebas P, Zolopa AR, Collier AC, Brown TT (2013) Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis 57(10):1483–1488. https://doi.org/10.1093/cid/cit538 CrossRefPubMedPubMedCentral

54.

Huang JS, Mulkern RV, Grinspoon S (2002) Reduced intravertebral bone marrow fat in HIV-infected men. AIDS 16(9):1265–1269. https://doi.org/10.1097/00002030-200206140-00009 CrossRefPubMed

Title: Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors
Authors: S. S. L. Goh
P. S. M. Lai
A. T. B. Tan
S. Ponnampalavanar
Publication date: 01-03-2018
Publisher: Springer London
Published in: Osteoporosis International / Issue 3/2018
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-017-4305-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors

Abstract

Summary

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Summary

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2018

Insights into the bisphosphonate holiday: a preliminary FTIRI study

Abaloparatide, a novel PTH receptor agonist, increased bone mass and strength in ovariectomized cynomolgus monkeys by increasing bone formation without increasing bone resorption

Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis

Interpretation of milk research results: response to comments by Michaelsson and Byberg

Effects of whole-body vibration on muscle strength, bone mineral content and density, and balance and body composition of children and adolescents with Down syndrome: a systematic review

Risk-equivalent T-score adjustment for using lumbar spine trabecular bone score (TBS): the Manitoba BMD registry